In Brief: SangStat Thymoglobulin
Executive Summary
SangStat Thymoglobulin: Rabbit antithymocyte globulin PLA accepted by FDA for review for the treatment of acute graft rejection episodes in kidney transplant recipients. SangStat filed the PLA on Jan. 6. The Menlo Park, Calif.-based company submitted an Establishment License Application in August which was also accepted for filing...